摘要目的 应用2型囊泡单胺转运体分子探针[18 F]-FP-(+)-DTBZ对2型糖尿病患者胰腺进行显像,探究2型糖尿病患者的β细胞总量(BCM),并探讨胰头和胰体尾部作为靶区域在糖尿病BCM评价方面的价值.方法 注射显像剂[18 F]-FP-(+)-DTBZ 40 min后,对8例2型糖尿病患者和7例正常对照者行20 min PET-CT检查,以脾脏作为参考组织计算胰头和胰体尾部标准化摄取比值(SUV ratio,SUVR).结果 2型糖尿病组胰头部平均SUVR(1.72±0.47),与胰体尾部平均SUVR(1.85±0.41)无统计学差异,正常对照组胰头平均SUVR(2.54±0.57)和胰体尾部平均SUVR(2.73±0.41)无统计学差异.但2型糖尿病组胰头部平均SUVR和胰体尾部平均SUVR较正常对照组胰头部(P=0.0088)和胰体尾部(P=0.0012)显著减低.结论 VMAT2靶点分子探针[18 F]-FP-(+)-DTBZ可用于2型糖尿病患者BCM的评价.

abstractsObjective The aim of this study was to evaluate theβ-cell mass ( BCM) in patients with type 2 diabetes mellitus( T2D) by PET/CT using [ 18 F]-FP-(+)-DTBZ, which is a vesicular monoamine transporter type 2 molecular probe. The feasibility of pancreatic head, body and tail as the target area was investigated for evaluation of the BCM in T2D. Methods 15 subjects ( 8 with T2D, and 7 as control) were involved in this study with 20 min static PET imaging at 40 min post injection of [ 18 F]-FP-(+)-DTBZ. The volume of interest ( VOIs) of pancreatic head, body and tail were drawn and quantitatively assessed. Spleens were collected as reference tissue for SUVR calculation. Results SUVR in the pancreatic head ( SUVR=1.72 ± 0.47) and pancreatic body, tail ( SUVR=1.85 ± 0.41) in T2D group was no significant difference, and no significant difference was observed in the pancreatic head (SUVR=2.54±0.57) and pancreatic body, tail(SUVR=2.73±0.41) in control group as well. In T2D group, a significant decreased SUVR was found in pancreatic head (P=0.0088) and pancreatic body and tail (P=0.0012) compared with controls. Conclusion The VMAT2 molecular probe [ 18 F]-FP-(+)-DTBZ can be used to evaluate BCM in patients with T2D.